Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atezolizumab and Cabozantinib in Recurrent Glioblastoma
NCT05039281Phase 2Active, not recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Sep 2022
- Primary completion
- Dec 2027
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of atezolizumab, cabozantinib in glioblastoma (GBM), Gliosarcoma (GS), sponsored by University of Texas MD Anderson Cancer Center. Started Sep 2022; status: active, not recruiting.
02
Drugs
atezolizumabcabozantinib
03
Conditions
glioblastoma (GBM)Gliosarcoma (GS)
Beyond the preview
Go deeper on NCT05039281.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05039281.